OTCMKTS:ZLDPF FY2027 EPS Estimate Boosted by William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) – William Blair boosted their FY2027 earnings per share (EPS) estimates for Zealand Pharma A/S in a report issued on Thursday, August 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of $7.31 per share for the year, up from their prior estimate of $7.00. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.19) per share.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. The firm had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $9.18 billion.

Other research analysts also recently issued reports about the company. Barclays raised Zealand Pharma A/S to a “strong-buy” rating in a report on Monday, July 7th. BNP Paribas raised Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, July 1st. Finally, Wells Fargo & Company raised Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. One equities research analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Strong Buy”.

Zealand Pharma A/S Trading Up 4.5%

ZLDPF stock opened at $57.50 on Friday. Zealand Pharma A/S has a 1-year low of $49.98 and a 1-year high of $141.74. The firm has a market cap of $4.08 billion, a P/E ratio of 4.04 and a beta of 0.71. The business’s 50 day moving average is $58.06 and its 200-day moving average is $71.10. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.